Brief: Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation For (Z)-Endoxifen For Mccune-Albright Syndrome
04/05/2026 13:34
May 4 (Reuters) - Atossa Therapeutics Inc ATOS.O: ATOSSA THERAPEUTICS RECEIVES FDA RARE PEDIATRIC DISEASE DESIGNATION FOR (Z)-ENDOXIFEN FOR MCCUNE-ALBRIGHT SYNDROME Source text: ID:nPn95gscNa Further company coverage: ATOS.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Atossa Therapeutics
See all newsAtossa Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary
Atossa Therapeutics Q3 net loss narrows as clinical trial expenses decline
Brief: Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation In Potential Priority Review Voucher Value
US RESEARCH ROUNDUP-Amrize, Dexcom, Lennar
Atossa Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary